← Leaderboards
Jaime F Modiano
Amc Cancer Research Center
$2,510,512
Attributed
$3,820,939
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $828.3K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,820,939 · 4
By mechanism
U01$2,620,855 · 1
R21$1,047,876 · 2
R03$152,208 · 1
Top collaborators
- Shruthi Naik7 shared
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaDiagnosisCanis FamiliarisMediatingResourcesMalignant NeoplasmsTumorComparativeGenomicsSamplingCellsRelapseT-LymphocytePathologyImmuneOncologyTranslationsMinnesotaHeterogeneityEngineeringImmunotherapyMutationResponseResponse Biomarker
Grant awards (13)
Translation of a novel combination therapy approach for non-Hodgkin lymphoma$460,749
U01 · FY2025 · CA
Translation of a novel combination therapy approach for non-Hodgkin lymphoma$121,055
U01 · FY2025 · CA
Translation of a novel combination therapy approach for non-Hodgkin lymphoma$643,654
U01 · FY2024 · CA
Translation of a novel combination therapy approach for non-Hodgkin lymphoma$114,223
U01 · FY2024 · CA
Translation of a novel combination therapy approach for non-Hodgkin lymphoma$70,432
U01 · FY2024 · CA
Translation of a novel combination therapy approach for non-Hodgkin lymphoma$625,851
U01 · FY2023 · CA
Translation of a novel combination therapy approach for non-Hodgkin lymphoma$584,891
U01 · FY2022 · CA
(PQ3) Modulation of Osteosarcoma Biology by Inflammation and Immunity Defined through a ComparativeApproach$166,388
R21 · FY2017 · CA · contact PI
Discovery and Pathogenetic Significance of Chromosome Translocations in Angiosarcom$76,208
R03 · FY2017 · CA · contact PI
(PQ3) Modulation of Osteosarcoma Biology by Inflammation and Immunity Defined through a ComparativeApproach$198,578
R21 · FY2016 · CA · contact PI
Discovery and Pathogenetic Significance of Chromosome Translocations in Angiosarcom$76,000
R03 · FY2016 · CA · contact PI
Role of Negative Regulation in Development of Diabetes$331,740
R21 · FY2003 · DK
Role of Negative Regulation in Development of Diabetes$351,170
R21 · FY2002 · DK